An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Replication-competent Adenovirus-mediated Double Suicide Gene Therapy
(Theragene®,Ad5-yCD/mutTKSR39rep-ADP) showed safety and anti-cancer effect in patients with
pancreatic cancer in phase I study.
From the experience of phase I study, the safety and efficacy of combination with standard
chemotherapy and radiation therapy with Theragene treatment will be assessed in this study.